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Abstract
The antibacterial activity of a series of nitric oxide (NO)-releasing poly(propylene imine) (PPI)
dendrimers was evaluated against both Gram-positive and Gram-negative pathogenic bacteria,
including methicillin-resistant Staphylococcus aureus. A direct comparison of the bactericidal
efficacy between NO-releasing and control PPI dendrimers (i.e., non-NO-releasing) revealed both
enhanced biocidal action of NO-releasing dendrimers and reduced toxicity against mammalian
fibroblast cells. Antibacterial activity for the NO donor-functionalized PPI dendrimers was shown
to be a function of both dendrimer size (molecular weight) and exterior functionality. In addition
to minimal toxicity against fibroblasts, NO-releasing PPI dendrimers modified with styrene oxide
exhibited the greatest biocidal activity (≥9.999% killing) against all bacterial strains tested. The N-
diazeniumdiolate NO donor-functionalized PPI dendrimers presented in this study hold promise as
effective NO-based therapeutics for combating bacterial infections.
Introduction
Bacterial infections in general pose tremendous challenges to human health in community
and nosocomial settings, particularly those originating from antibiotic-resistant strains.1–3
Dendrimers are a family of macromolecular scaffolds with hyper-branched architectures and
multivalent surfaces4–12 that have been used for a broad range of biomedical applications
including drug delivery,13–21 gene transfection,22–27 and tissue engineering.28–31 Examples
of dendritic scaffolds used for biomedical applications include poly(propylene imine) (PPI),
polyamidoamine (PAMAM), poly(L-lysine) (PLL), polyesters, and poly(2,2-
bis(hydroxymethyl)propionic acid.6 Recent research has highlighted the versatility of
dendrimer synthesis to create antibacterial dendritic scaffolds of unique size and surface
functionality.14–17,32 For example, Cooper and coworkers synthesized quaternary
ammonium-functionalized poly(propylene imine) (PPI) dendrimers and demonstrated their
antimicrobial activity as a function of dendrimer size and quaternary ammonium structure.15
Despite promising biocidal activity, the cationic dendrimers were inherently toxic to
mammalian cells. In an effort to design less toxic constructs, Cai and coworkers partially
modified the exterior of primary amine-functionalized polyamidoamine dendrimers
(PAMAM-NH2) with poly(ethylene glycol) (PEG) to mask the peripheral cationic
charge.14,17 The resulting PEG-modified PAMAM conjugates exhibited reduced toxicity to
human corneal epithelial cells, while maintaining their antibacterial efficacy against several
bacterial species. Anionic amphiphilic dendrimers have also been shown to selectively kill
Gram-positive Bacillus subtilis with minimal toxicity to human umbilical vein endothelial
cells (HUVECs).16
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Nitric oxide (NO), a phagocyte-derived, reactive free radical plays key roles in the host
defense against microbial pathogens.33–36 Broad-spectrum antibacterial activity results from
reactive byproducts of NO (e.g., peroxynitrite and dinitrogen trioxide) that negatively
impact the integrity of the bacteria membrane and cell function via oxidative and nitrosative
stress. The design of NO-based macromolecules thus represents an active area of research in
the development of next generation antibacterial agents and other therapeutics.37–41 For
example, our group has prepared a number of macromolecular NO donors including gold
clusters,42,43 dendrimers,44–46 and silica-based nanoparticles47–51 to facilitate improved
storage and delivery for therapeutic applications. Hetrick et al. first reported on the enhanced
antibacterial properties of macromolecular-derived NO compared to small molecule NO
donors.52 In subsequent work, Carpenter et al. described the importance of particle size on
biocidal activity against Gram-negative Pseudomonas aeruginosa.50 Collectively, this earlier
work illustrates the advantage of killing microbial pathogens with macromolecular NO
donors.
To further diversify the available macromolecular NO donor vehicles, we reported the
synthesis of structurally diverse N-diazeniumdiolate-functionalized poly(propylene imine)
(PPI) dendrimers capable of tunable NO storage and release (0.9–3.8 μmol NO·mg−1 totals
and 0.3 to 4.9 h half-lives).44,46 However, an evaluation of the bactericidal activity of these
structurally diverse NO-releasing PPI dendrimers was not carried out. We hypothesize that
both the size and exterior functionality may enable tuning of both the biocidal activity and
cytotoxicity for antibacterial applications.
Methods
Materials
Propylene oxide (PO), styrene oxide (SO), poly(ethylene glycol) methyl ether acrylate
(average Mn = 480) (PEG), and propidium iodide (PI) were purchased from Sigma-Aldrich
(St. Loius, MO). Sodium methoxide (5.4 M solution in methanol) was obtained from Acros
Organics Geel, Belgium). Common laboratory salts and solvents were purchased from
Fisher Scientific (Pittsburgh, PA). Unless noted otherwise, these and other materials were
used as received without further purification. Tryptic soy broth (TSB) and tryptic soy agar
(TSA) were obtained from Becton, Dickison and Company (Franklin Lakes, NJ).
Rhodamine B isothiocyanate (RITC) was purchased from Aldrich Chemical Co.
(Milwaukee, WI). Spectra/Por Float-A-Lyzers for dialysis of the dendrimers were purchased
from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). 4,5-Diaminofluorescein
diacetate (DAF-2 DA) was purchased from Calbiochem (San Diego, CA). Glass bottom
microscopy dishes were received from MatTek Corporation (Ashland, MA).
Synthesis of Secondary Amine- and Diazeniumdiolate-Functionalized PPI Dendrimers
Secondary amine-functionalized PPI dendrimers (G2 and G5) were synthesized as described
previously.44,46 Briefly, 100 mg primary amine-functionalized G2-PPI dendrimer 7 (G2-
PPI-NH2) was dissolved in methanol (2 mL). One molar equivalent of PO, SO, or PEG was
then added to the G2-PPI-NH2 solution (methanol) with constant stirring at room
temperature for 4 d to yield the secondary amine-functionalized G2-PPI conjugates (i.e., G2-
PPI-PO 1, G2-PPI-PEG 3, G2- PPI-SO 5). Likewise, secondary amine-functionalized G5-
PPI conjugates (i.e., G5-PPI-PO 2, G5- PPI-PEG 4, G5-PPI-SO 6) were formed via the
reactions of G5-PPI-NH2 8 with PO, PEG, and SO, respectively. Solvent was then removed
under reduced pressure. Dendrimers 1–6 were dissolved in water followed by dialysis
against water and lyophilization. The resulting secondary amine-functionalized dendrimers
1–6 (Figure 1) were characterized by 1H and 13C nuclear magnetic resonance (NMR)
spectroscopy using Bruker (400 MHz) and Varian (600 MHz) spectrometers.
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Representative 1H and 13C NMR data of secondary amine-functionalized G5-PPI conjugates
formed via the reactions of G5-PPI-NH2 8 with PO, PEG, and SO (G5-PPI-PO 2, G5-PPI-
PEG 4, G5-PPI-SO 6) are as follows: G5-PPI-PO 2: 1H NMR (400 MHz, CD3OD, δ): 3.70
(CH2CH(OH)CH3), 2.60–2.62 (CH2CH(OH)CH3, NCH2CH2CH2NH), 2.40
(NCH2CH2CH2NH), 1.60 (NCH2CH2CH2NH), 1.00 (CH2CH(OH)CH3). 13C NMR (400
MHz, CD3OD, δ): 66.9, 58.2, 53.7, 52.8, 41.2, 30.8, 27.6, 24.9, 21.8. G5-PPI-PEG 4: 1H
NMR (400 MHz, CD3OD, δ): 2.60 (NCH2CH2CH2NH), 2.40 (NCH2CH2CH2NH), 1.60
(NCH2CH2CH2NH), 3.40–3.70 (OCH2CH2O), 2.80 (CH2NHCH2CHCOOPEG), 2.65
(CH2NHCH2CHCOOPEG), 2.42 (CH2NHCH2CHCOOPEG). 13C NMR (400 MHz,
CD3OD, δ): 172, 71.6, 70.85, 69.3, 60.1, 57.0, 51.4, 43.9, 39.1, 22.9. G5-PPI-SO 6: 1H
NMR (400 MHz, CD3OD, δ): 7.50–7.20 (CH2CH(OH)Ph), 3.70 (CH2CH(OH)Ph), 2.72
(CH2CH(OH)Ph), 2.60 (NCH2CH2CH2NH), 2.40 (NCH2CH2CH2NH), 1.60
(NCH2CH2CH2NH). 13C NMR (400 MHz, CD3OD, δ): 140.6, 128.2, 127.5, 127.3, 125.8,
71.9, 57.1, 52.4, 45.6, 39.8, 26.3, 23.6.
For the synthesis of N-diazeniumdiolate-functionalized PPI dendrimers 1a–6a, one
equivalent of 5.4 M sodium methoxide solution in methanol (with respect to the molar
amount of primary amine functionalities in PPI-NH2 used to synthesize dendrimers 1–6)
was added to a vial containing dendrimers 1–6 in methanol (2 mL). After placing the vial in
a stainless steel reactor, the headspace was flushed with argon three times followed by three
longer purges with argon (3 × 10 min) to remove oxygen from the stirred solution. The
reactor was then filled with NO (10 atm) (purified over KOH pellets for 30 min to remove
trace NO degradation products) at ambient temperature. After 3 d, the NO was expunged
using the same argon flushing procedure described above to remove unreacted NO from the
reaction solution. The formation of the N-diazeniumdiolate functionality was confirmed by
UV-vis spectroscopy (Perkin-Elmer Lambda 40 spectrophotometer (Norwalk, CT)) with the
presence of a strong absorbance peak at ~250 nm (solution in methanol). Zeta potential of
the dendrimers was determined using a Zetasizer Nano ZS Zeta Potential Instrument
(Malvern, UK). Samples (~2 mg·mL−1) were prepared in phosphate buffer (10 mM, pH =
7.4) and immediately injected into a folded capillary cell for zeta-potential analysis.50
Characterization of NO Storage and Release
Nitric oxide release was measured using a Sievers 280i Chemiluminescence Nitric Oxide
Analyzer (Boulder, CO). Chemiluminescence was the chosen measurement technique as it
measures NO levels directly and minimizes side reactions that can occur prior to
analysis.40,53 The NO analyzer was calibrated using an atmospheric (blank) sample passed
through an NO zero filter and a 26.8 ppm NO standard. Aliquots (~10–25 μL) of N-
diazeniumdiolate-functionalized PPI 1a–6a as a solution in methanol (~7–200 mM) were
added to 30 mL phosphate buffered saline (PBS) (10 mM, pH = 7.4) at 37 °C to initiate NO
release. The analysis was terminated when the NO release fell below 10 ppb NO·mg−1
dendrimer. Chemiluminescence data for the NO-releasing dendrimers were represented as: i)
total amount of NO release (t[NO], μmol NO·mg−1, and μmol NO·μmol−1 of secondary
amine-functionalized dendrimers); ii) amount of NO released over the 2 h time course of the
bactericidal assays (t[NO]2h, μmol NO·mg−1, and μmol NO·μmol−1 of secondary amine-
functionalized dendrimers); iii) maximum flux of NO release ([NO]max, ppb·mg−1, and
ppb·μmol−1 of secondary aminefunctionalized dendrimers); iv) time required to reach
[NO]max (tm); v) half-life (t1/2) of NO release; and, vi) conversion efficiency defined as
percentages of amine functionalities in PPI conjugates 1–6 converted to N-diazeniumdiolate
functionality (i.e., total moles of NO release divided by twice the molar amount of primary
amine functionalities in G2 and G5 PPI-NH2 used to initially synthesize secondary amine-
functionalized dendrimer conjugates).
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The bacterial strains used in this study were obtained from American Type Culture
Collection (ATCC; Manassas, VA) and included Pseudomonas aeruginosa (19143), tandard
Staphylococcus aureus (29213), and methicillin-resistant S. aureus (MRSA) (33591).
Lyophilized bacteria were reconstituted in TSB and cultured overnight at 37 °C. A 0.5 mL
aliquot of culture was grown in 50 mL of TSB for 2–4 h until reaching an optical density at
600 nm (OD600) of 0.1–0.5. The resulting culture was pelleted by centrifugation,
resuspended in 15% glycerol (v/v in PBS), and stored at −80 °C in 1 mL aliquots. For daily
experiments, colonies of bacteria culture were inoculated in 2 mL of TSB overnight at 37 °C
and recultured in fresh TSB the next day. The bacteria were then grown to mid-exponential
phase (~1 × 108 colony forming units (cfu)·mL−1) as determined by OD600 measurements.
The relationship between the OD600 and the concentration of bacteria in the culture
suspension was calibrated for each strain using a Spectronic 301 spectrophotometer (Milton
Roy; Ivyland, PA) and enumeration of colony forming units from culture dilutions grown on
TSA plates. The resulting 1 × 108 cfu·mL−1 bacterial suspension in TSB was centrifuged for
15 min at 3645 × g, followed by decanting of the supernatant. The pellet of bacterial cells
was resuspended in PBS and adjusted to an appropriate concentration in PBS.
Bactericidal Assays
The minimum bactericidal concentration (MBC) was determined as the concentration of
dendrimers that resulted in either a 3 or 5 log reduction in viability compared to untreated
cells for a particular bacterial strain after 2 h. Each strain of bacteria was tested in triplicate
over an optimized concentration range. To evaluate the bactericidal efficacy of primary and
secondary amine-functionalized dendrimers 1–8, solutions of dendrimers in PBS (10 mM,
pH = 7.4) or acetate buffer (20 mM, pH = 5.0, for dendrimers 5 and 6 to increase long-term
solubility) were prepared and added to an appropriate volume of bacterial suspension in PBS
for a final starting innoculum concentration of 1 × 106 cfu·mL−1. To test the bactericidal
properties of NO-releasing dendrimers 1a–6a, an appropriate volume of dendrimer solution
in methanol was premeasured into a glass vial and dried under vacuum for 2 h. The
necessary volume of 1 × 106 or 1 × 107 cfu·mL−1 bacterial suspension (3 and 5 log reduction
testing, respectively) was then added to obtain the target dendrimer concentration. The
starting innoculum concentration (1 × 106 or 1 × 107 cfu·mL−1) for 3 or 5 log reduction
testing was selected on the basis of the limit of detection for plating (2.5 × 103 cfu·mL−1).54
After 2 h of incubation at 37 °C, bacterial culture dilutions were prepared in PBS. A
predetermined aliquot (100 μL) of each dilution was plated onto TSA plates and incubated
at 37 °C overnight. The number of colonies was enumerated to determine cell viability at the
time of plating.
Confocal Microscopy for Detection of Intracellular NO and Cell Death
N-diazeniumdiolate-modified N-(6-aminohexyl) aminopropyltrimethoxysilane (AHAP3)/
tetraethoxysilane (TEOS) silica nanoparticles (50 nm) were synthesized as described
previously.50 P. aeruginosa was cultured in TSB to a concentration of 1 × 108 cfu·mL−1,
collected via centrifugation (3645 × g for 10 min), resuspended in sterile PBS, and adjusted
to 1 × 106 cfu·mL−1 in PBS supplemented with 10 μM DAF-2 DA and 30 μM PI. Aliquots
of the bacteria solution were incubated in a glass bottom confocal dish for 45 min at 37 °C.
A Zeiss 510 Meta inverted laser scanning confocal microscope with a 488 nm Ar excitation
laser (2.0% intensity) and a BP 505–530 nm filter was used to obtain DAF-2 (green)
fluorescence images. A 543 nm HeNe excitation laser (25.3% intensity) with a BP 560–615
nm filter was used to obtain PI (red) fluorescence images. The bright field and fluorescence
images were collected using a N.A. 1.2 C-apochromat water immersion lens with a 40×
objective. Suspensions (1.5 mL) of G2 (17.4 μg·mL−1) or G5 (20.0 μg·mL−1) PPI-SO NO-
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releasing dendrimers or 50 nm NO-releasing AHAP3/TEOS nanoparticles (44.0 μg·mL−1)
in PBS supplemented with 10 μM DAF-2 DA and 30 μM PI were added to the bacteria
solution (1.5 mL) in the glass confocal dish. Images were collected every 2 min to observe
intracellular NO concentrations and bacteria cell death temporally.
Confocal Microscopy for Association of Dendrimers with Bacteria Cells
The synthesis of fluorescently labeled control or NO-releasing G2-PPI-PO dendrimers was
adapted from a previously reported literature procedure.50 Briefly, G2-PPI-NH2 (100 mg)
and rhodamine B isothiocyanate (RITC) (7.5 mg, 14.0 mmol) were dissolved in methanol (2
mL). The solution was stirred for 24 h in the dark. The product solution was concentrated
under reduced pressure, dissolved in water (~3 mL), and added to a Spectra/Por Float-A-
Lyzer (5 mL, 1000 MWCO) for dialysis in 0.1 M NaCl (2 L) for 24 h, followed by dialysis
in ultrapure Milli-Q water for 3 d (3 × 2 L). The aqueous sample was frozen and lyophilized
to yield RITC-labeled G2-PPI-NH2. Next, fluorescently labeled G2-PPI-NH2 was modified
with one molar equivalent of PO alone and/or further reacted with high-pressure NO under
basic conditions as described above to yield RITC-labeled control and NO-releasing G2-
PPI-PO dendrimers. S. aureus was cultured in TSB to a concentration of 1 × 108 cfu·mL−1,
collected via centrifugation (3645 × g for 10 min), resuspended in sterile PBS, and adjusted
to 1 × 106 cfu·mL−1. Aliquots of the bacteria solution were incubated in a glass bottom
confocal dish for 45 min at 37 °C. A Zeiss 510 Meta inverted laser scanning confocal
microscope with a 543 nm HeNe excitation laser (80% intensity) and a LP 585 nm filter was
used to obtain fluorescence images of the RITC-modified dendrimers. The bright field and
fluorescence images were collected using a N.A. 1.2 C-apochromat water immersion lens
with a 40× objective. Solutions of RITC-labeled control (400 μg·mL−1) or NO-releasing G2
(400 μg·mL−1) PPI-PO dendrimers in PBS (1.5 mL) were added to the bacteria solution (1.5
mL) in the glass confocal dish to achieve a final concentration of 200 μg·mL−1. Images were
collected every 2 min to monitor association of the dendrimers with S. aureus temporally.
In Vitro MTS Cell Proliferation Assay
Mouse fibroblast cells (L929) were purchased from American Type Culture Collection
(ATCC; Manassas, VA). Initial seeding densities of 30,000 cells·mL−1 in 200 μL of growth
medium (Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS),
penicillin 100 units·mL−1, and streptomycin 100 μg·mL−1) were used in clear 96-well
culture plates. After plating, all cells were incubated at 37 °C for 48 h with toxicity
experiments carried out at ~80% confluence. Dendrimer solutions (50 μL) in chilled 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffer (HEPES; 20 mM, pH = 7.4) or acetate
buffer (20 mM, pH = 5.0, for dendrimers 5 and 6) were prepared in triplicate at desired
concentrations and added to cells immediately after an initial replacement of growth media
with fresh media (200 μL). Cells were incubated with dendrimers for 4 h before aspirating
the media from all samples. Fresh media (100 μL) was added to the cells along with 20 μL
of the MTS assay reagent (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay,
Promega, Madison, WI). The mitogenic MTS assay for cell viability relies upon the
reduction of a yellow MTS compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) due to mitochondrial
respiration. The reduction to a purple formazan derivative occurs only in viable cells. The
absorbance of this colored solution was quantified at 490 nm using a Labsystems Multiskan
RC microplate spectrophotometer (Helsinki, Finland). Untreated cells were used as controls.
Results were expressed as percentage of relative cell viability = [(Abs490 of dendrimer
treated cells − Abs490 of blank)/(Abs490 of untreated cells − Abs490 of blank)] × 100%.
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Characterization of Nitric Oxide Release from Dendrimer-Bound N-Diazeniumdiolates
Recent research suggests that both the size and exterior functionality of dendrimer scaffolds
may play important roles in their antibacterial activity.14–17 As such, we synthesized NO-
releasing PPI dendrimers of distinct size and exterior properties (e.g., aromatic, hydrophilic,
hydrohphobic) to design antibacterial scaffolds with minimal toxicity to healthy cells
(Figure 1).44,46
Briefly, the dendrimer exterior of G2 or G5 PPI-NH2 was modified with PO or SO via a ring
opening reaction or PEG via conjugate addition to yield secondary amine-functionalized
dendrimers 1–6. The use of epoxides and acrylates for dendrimer modification allows for the
tailoring of the exterior functionality with respect to steric environment, hydrophobicity, and
biocompatibility. Subsequent reaction of accessible secondary amines with high-pressure
NO under basic conditions resulted in the formation of N-diazeniumdiolate-functionalized
dendritic scaffolds 1a–6a with suitable amine-to-diazeniumdiolate conversion efficiencies
(~19–35%) and NO payloads (~1.1–3.8 μmol·mg−1) (Table 1). The practical advantage of
this synthetic approach is that it allows for i) the direct comparison of antimicrobial
properties of NO-releasing dendrimers with secondary amine-functionalized control
dendrimers (i.e., non-NO-releasing); and, ii) the identification of structural motifs at the
dendrimer exterior that may influence the bactericidal efficacy of these materials. As
determined using chemiluminescence, the NO-release kinetics from these macromolecular
NO-donor scaffolds were similar regardless of size or exterior modification, with NO release
half-lives (t1/2) ranging from ~0.7–1.7 h and the time required to reach the maximum NO
flux (tm) from ~1.5–3 min (Table 1). To understand the influence of N-diazeniumdiolate
conversion on the dendrimer surface charge, the zeta potentials of control and NO-releasing
dendrimers in phosphate buffer (10 mM, pH = 7.4) were quantified (Table 2). As expected,
control dendrimers 1–6 exhibited positive zeta potentials (~+7–26 mV) due to the
protonation of exterior secondary amines at pH 7.4. Less positive and even negative zeta
potentials (~−14 to +13 mV; listed in bold) were measured for NO-releasing dendritic
scaffolds 1a–6a since the amines were functionalized with N-diazeniumdiolate NO donors.
Multivalent dendrimer-bound NO donors with 8 and 64 terminal functional groups (G2 and
G5) were employed to understand the influence of dendrimer size on bactericidal efficacy.
To compare the localized concentration of NO delivered into solution from a single dendritic
scaffold of two different sizes, the maximum NO flux ([NO]m, ppb) and the amount of NO
generated (t[NO]2h, μmol) during 2 h bactericidal assays were determined on a per
micromole basis. As shown in Table 1, the larger dendritic scaffolds exhibited markedly
greater NO flux (~4–6 folds) and release levels (~8–10×) over 2 h (noted in bold) than their
smaller analogues. This data reveals the ability of NO-releasing PPI dendrimers to deliver
large localized doses of NO as a function of dendrimer size, a potential benefit for fine-
tuning antimicrobial activity.
Broad-Spectrum Bactericidal Efficacy of NO-Releasing Dendrimers
Gram-negative (P. aeruginosa), Gram-positive (S. aureus), and antibiotic-resistant species
(MRSA) were exposed to control 1–6 and NO-releasing dendrimers 1a–6a to evaluate the
ability of dendrimers to kill bacteria. Bacterial viability assays were performed under static
conditions to determine the lowest dendrimer concentration (MBC) required to elicit a 3-log
reduction. Although methanol (used as a solvent in the dendrimer synthesis) was removed
thoroughly under reduced pressure and lyophilization, the toxicity of methanol to both
Gram-negative P. aeruginosa and Gram-positive S. aureus was also evaluated to ensure that
any residual methanol did not influence MBC values. No methanol toxicity up to 5000 μM
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methanol (e.g., markedly greater than the dendrimer concentrations used in this study) was
observed over the 2-h time course of the bactericidal assay.
The amount of NO delivered over 2 h from dendrimers 1a–6a (t[NO]2h, μmol NO·μmol−1
of dendrimers; Table 1) was also employed to quantitatively assess the NO dose necessary
to achieve 99.9% bacterial killing. Figure 2 illustrates the dose-dependent bactericidal
activity for both control and NO-releasing dendrimers against Gram-negative P. aeruginosa.
The corresponding NO release at specific concentrations of NO-releasing dendrimers (μmol
NO·L−1) was derived by multiplying t[NO]2h (μmol NO·μmol−1 of dendrimers; Table 1)
with the concentrations of the dendrimers (μM). The MBCs and the bactericidal NO doses
required for these dendrimers are provided in Table 3 (i.e., the bactericidal NO dose (μmol
NO·L−1) = t[NO]2h (μmol NO·μmol−1 of dendrimers; Table 1) ×MBC (μM)). In general,
the concentration of NO-releasing dendrimers 1a–6a required to eradicate (completely kill)
P. aeruginosa was substantially lower than that of control dendrimers 1–6, indicating
enhanced bactericidal action exerted by NO. This increase in bactericidal efficacy may be
attributed to both oxidative and nitrosative stresses on the bacteria, driven by reactive NO
byproducts such as dinitrogen trioxide (N2O3) and peroxynitrite (ONOO−).33,34,52,55 While
oxidative stress leads to membrane destruction via peroxynitrite-induced lipid peroxidation,
nitrosative stress (exerted by reactive byproducts such as N2O3) may result in protein S-
nitrosation and DNA deamination, also disrupting microbial viability. As expected, the NO
poses a biocidal action on the bacteria.
Further inspection of these data reveals that the bactericidal concentrations for both NO-
releasing and control dendrimers (G2 or G5) varied substantially as a function of their
exterior functionality. For example, both NO-releasing and control G2-PPI-SO dendrimers
(5a and 5) exhibited the greatest bactericidal efficacy against P. aeruginosa as evidenced by
the lowest concentration of dendrimers required for complete killing (1.0 and 5.0 μM,
respectively). As shown in Figure 2A, intermediate efficacy was observed for the NO-
releasing and control G2-PO-modified PPI conjugates (1a and 1) (300 and 400 μM,
respectively). The G2-PEG-modified scaffolds (3a and 3) were least effective, requiring the
largest dendrimer concentrations for P. aeruginosa killing (320 and 4800 μM for NO-
releasing and control scaffolds, respectively) (Figure 2C). Similar trends were observed for
the larger (G5) NO-releasing and control dendrimers (Figures 2B, D, F).
Cooper and coworkers have attributed the bactericidal action of cationic dendritic scaffolds
to the disruption of the cytoplasmic membrane of the bacteria, initially by dendrimer
association with the bacterial outer surface and then dendrimer penetration through the cell
walls.15,56 The mechanism by which this initial association occurs is largely dependent on
electrostatic and hydrophobic interactions between the cationic dendrimers and the
negatively-charged outer membrane of the bacteria. As such, the low bactericidal activity
observed for PEG-modified dendrimers is the result of decreased electrostatic interactions
between the dendrimer scaffold and the bacteria since the exterior PEG groups greatly
reduce the positive surface charge of the scaffold. As indicated by a more positive zeta
potential (Table 2), we hypothesize that the enhanced bactericidal activity of the SO-
modified dendrimers is the result of increased electrostatic interactions between the
dendrimers and bacteria, and thus more effective (i.e., localized) NO release. Others have
reported that the balance between hydrophilic and lipophilic regions within their chemical
structures influences the antimicrobial properties of cationic dendrimers.14,15 Indeed, the
improved bacteria killing observed for SO-modified dendrimers may be attributed, at least
partially, to the increased exterior hydrophobicity compared to PO- or PEG-modified
dendrimers. In addition to cytoplasmic membrane disruption, Lucchini et al. reported that
small molecule benzyl and phenethyl alcohols greatly influenced protein synthesis related to
protein function.57 Thus, the enhanced efficacy of the SO-modified dendrimers may also
Sun et al. Page 7













result from the multivalent benzyl alcohol-like moieties altering bacteria protein synthesis.
Of note, confirming such mechanism is beyond the scope of this work.
As shown in Table 3, the NO dosage necessary for complete bacterial killing over 2 h was
significantly lower for the larger dendrimers (e.g., 284 vs 897 μmol NO·L−1 for G5 and G2
PPI-PO 2a and 1a, respectively). The greater efficacy observed for the larger scaffolds
results from the increased density of N-diazeniumdiolate functionalities, enabling greater
localized NO delivery in close proximity to the bacterial cells. Although noted for both PPI-
PO and PPI-PEG analogues, the NO dose required for G5 PPI-SO 6a to kill P. aeruginosa
(7.6 μmol NO·L−1) was greater than that required from the corresponding smaller analogue
5a (2.0 μmol NO·L−1). The enhanced efficacy for the G2 PPI-SO 6a may result from faster
diffusion of the smaller aromatic-modified scaffold into/across the bacterial cell walls
despite lower NO donor density. In addition, the amount of NO required for complete
bacterial killing (3-log reduction for P. aeruginosa) is significantly less for both G2 and G5-
SO-modified dendrimers (2.0 and 7.6 μmol NO·L−1, respectively) compared to previously
reported 50 nm AHAP3/TEOS nanoparticles (376 μmol NO·L−1).50
To confirm whether the enhanced bactericidal efficacy of the smaller NO-releasing G2- PPI-
SO 5a was due to faster scaffold diffusion into P. aeruginosa cells, and thus enhanced
efficiency of NO delivery, intracellular NO concentrations were visualized temporally using
confocal microscopy and an NO sensitive dye, 4,5-diaminofluorescein diacetate (DAF-2
DA). Briefly, DAF-2 DA is membrane-permeable until hydrolyzed internally by
intracellular esterases to an impermeable form, 4,5-diaminofluorescein (DAF-2).52 In the
presence of oxygen and NO, DAF-2 is converted to a green fluorescent derivative,
triazolofluorescein. Bacteria were also imaged in the presence of propidium iodide (PI), a
dye that permeates compromised cell membranes.52 After PI passes through the cell
membrane, it binds nucleic acid material, resulting in red fluorescence. In this regard, PI
entering the cell indicates a compromised membrane and cell death. In the absence of the
NO-releasing scaffolds, the cells were imaged with both DAF-2 DA and PI using identical
laser settings; dendrimer autofluorescence was not observed throughout the time course of
the experiment (see Figure S1; Supporting Information). These results served as negative
controls for the study.
The NO-releasing dendrimers were introduced to the suspension of P. aeruginosa cells at an
NO dosage of 10 μmol·L−1. As expected, the DAF-2 signal for the faster diffusing, G2-PPI-
SO 5a appeared first at 46 min, followed by the appearance of the DAF-2 signal for the G5-
PPI-SO dendrimer 6a at 60 min (Figure 3). Indeed, the smaller G2 5a dendrimers resulted in
more efficient NO delivery to the bacterium. To facilitate comparison of NO delivery from
the dendrimers with silica scaffolds, we also exposed the P. aeruginosa cells to 50 nm
AHAP3/TEOS silica nanoparticles at a similar NO dosage (10 μmol·L−1).50 Green
fluorescence was observed at 60 min for the 50 nm AHAP3/TEOS silica particles, signaling
an increase in intracellular NO. However, the fluorescence intensity was always less than
that observed for the dendrimers throughout the time course of the experiment indicating
less efficient NO delivery to the interior of the bacteria relative to the dendrimer scaffolds.
In addition to intracellular NO visualization, we also observed red fluorescence (from PI) for
P. aeruginosa cells with compromised membranes. For the NO-releasing G2-PPI-SO
dendrimer 5a, red fluorescence was observed after 64 min. Red fluorescence (PI signal) for
the slower diffusing NO-releasing G5-PPI-SO dendrimer 6a appeared at 94 min. Of note, PI
signal was not visualized in P. aeruginosa cells after exposure to the NO-releasing 50 nm
AHAP/TEOS particles at 94 min. We hypothesize that the larger silica scaffold was unable
to deliver NO to the bacteria cells at concentrations necessary to compromise the membrane
and allow for PI penetration. In contrast, the dendritic scaffold facilitated more efficient NO
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delivery to and across the cell surface (membrane), resulting in enhanced bactericidal
efficacy.
The bactericidal efficacy of the dendrimers was also assessed using Gram-positive S. aureus.
As expected based on NO’s broad-spectrum activity,33 the NO-releasing dendritic scaffolds
also exhibited greater bactericidal efficacy against S. aureus compared to control dendrimers
(Figure 4 and Table 4), analogous to the behavior observed with Gram-negative bacteria (P.
aeruginosa). Of note, a greater concentration of NO-releasing G2-PPI-PO 1a was required to
completely kill all S. aureus cells compared to the control G2-PO-modified dendrimer 1.
These results may be attributed to the decreased interactions between the dendrimer and
bacterial membrane resulting from the negative zeta potential of the NO-releasing G2-PPI-
PO 1a (−14.0±5.4 mV; Table 2).
To confirm whether the lessened antibacterial activity of the NO-releasing G2-PPI-PO 1a
was indeed the result of decreased dendrimer interactions (with the S. aureus cell
membrane), confocal microscopy was used to compare the association kinetics of NO-
releasing G2-PPI-PO 1a and control PO-modified dendrimer 1 (zeta potential = +7.1±0.6
mV; Table 2) with the bacteria cells. Rhodamine isothiocyanate (RITC)-labeled control and
NO-releasing G2-PPI-PO dendrimers (1 and 1a) (400 μg·mL−1) were added to the bacteria
cell suspension and images were collected every 2 min. As expected, control dendrimer 1
associated with the S. aureus cells rapidly (4 min) while the time required for association of
the NO-releasing dendrimer 1a with the bacteria was greater (12 min; Figure 5). In all
experiments, the red fluorescence intensity increased as the degree of association between
the dendrimers and bacteria increased. Of note, the fluorescence for the control dendrimer 1
was greater than that for the corresponding NO-releasing dendrimer 1a even after 45 min,
indicating that the NO-releasing dendrimers do not associate as readily. These observations
confirm that interactions between the NO-releasing G2-PPI-PO dendrimers and S. aureus
were less than that of the controls, further corroborating the efficacy observed with the
bactericidal assays.
The specific exterior modification was also found to influence the bactericidal efficacy
against S. aureus, with SO- and PEG-modified dendrimers having the greatest and least
effects, respectively, analogous to what we observed with P. aeruginosa. As well, NO
delivered from G5 dendrimers exhibited greater bactericidal efficacy than that from the
smaller (G2) analogues (Table 4), reaffirming that N-diazeniumdiolate NO donor density
and greater localized NO delivery benefited S. aureus killing.
As shown in Tables 3 and 4, the G5 dendrimer concentrations required to kill the Gram-
positive bacteria (S. aureus) were generally less than that needed to eradicate P. aeruginosa.
The improved antimicrobial efficacy for G5 dendrimers against Gram-positive over Gram-
negative bacteria likely arises from their distinct cell-envelope organization. Gram-negative
bacteria have an additional lipid membrane barrier that may reduce the diffusion of
macromolecular scaffolds. Chen et al. reported similar results with larger molecular weight
dendrimers (e.g., quaternary ammonium-modified PPI conjugates) being less effective at
diffusing across extracellular barriers of Gram-negative bacteria (E. coli) compared to
Gram-positive S. aureus.15 The enhanced efficacy of the dendrimers against the Gram-
positive S. aureus is in marked contrast to our previous report describing more effective
killing of Gram-negative bacteria using a small molecule NO donor (PROLI/NO).58 Both
Gram-negative P. aeruginosa and Gram-positive S. aureus were susceptible to control
primary amine-functionalized PPI dendrimers, corroborating the results reported by others
using primary amine-functionalized PAMAM conjugates (PAMAM-NH2) as antibacterial
agents.14,17 The inherent biocidal action of primary amine-functionalized controls is the
result of both electrostatic (protonated primary amines) and hydrophobic interactions
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between dendrimers and the negatively-charged bacteria, leading to increased permeability
and disruption of the cytoplasmic membrane.
Gaseous NO and NO generated from small molecule NO donors (e.g., PROLI/NO) have
exhibited bactericidal efficacy against methicillin-resistant S. aureus (MRSA), indicating the
potential of NO to kill antibiotic-resistant pathogens.36,58 To determine if NO-releasing
dendrimers were effective against MRSA, bactericidal assays were carried out using SO-
modified dendrimers (selected based on their biocidal activity against standard S. aureus).
As shown in Figure 6, NO-releasing SO-modified G2 and G5 dendrimers (5a and 6a)
proved effective against MRSA at lower dendrimer concentrations than control analogues
(3-log killing at 2.5 and 0.25 μM for 5a and 6a vs. 5 and 0.5 μM for 5 and 6, respectively).
These results are comparable to those observed for standard S. aureus.
Antibacterial therapeutics with maximal bactericidal efficacy are often necessary to
circumvent the emergence of bacterial resistance.59 In this context, we evaluated the ability
of NO-releasing dendrimers (e.g., N-diazeniumdiolate-modified PPI-SO conjugates) to
reduce bacterial viability by 5 orders of magnitude (i.e., ≥99.999% killing). As shown in
Table 5, both G2 and G5 NO-releasing PPI-SO (5a and 6a) exhibited biocidal activity over
5 logs against Gram-negative (P. aeruginosa), Gram-positive (S. aureus), and the
methicillin-resistant (MRSA) pathogen, albeit at concentrations marginally greater than
those necessary to achieve 3-log killing. The ability to achieve ≥99.999% killing further
illustrates the potential of NO-releasing dendrimers as highly effective antibacterial
therapeutics.
Cytotoxicity of NO-Releasing Dendrimers against Mammalian Fibroblasts
An inherent toxicity against healthy mammalian cells represents a shortcoming of most
dendrimer constructs.60–65 To determine the influence of size (i.e., generation number or
molecular weight) and exterior functionality on the toxicity of NO-releasing dendrimers, the
in vitro cytotoxicity of both control and NO-releasing dendritic scaffolds was evaluated
using a standard MTS cell proliferation assay (L929 mouse fibroblasts).66 L929 cells are
common for in vitro cytotoxicity studies due to their prevalence in wound healing and
extracellular environments.61,67,68 A range of concentrations for control and NO-releasing
dendrimers was tested to encompass the minimum and twice the minimum concentration of
each dendrimer that proved 3-log killing of bacteria against all strains tested. As shown in
Figure 7, G5 control dendrimers were found to present significant toxicity to the L929
fibroblasts (e.g., <20% viability) when administered at concentrations necessary to kill
bacteria. While both G2-PPI-PO 1 and G2-PPI-NH2 7 exhibited minimal toxicity to
fibroblast cells at bactericidal concentrations, administering twice the minimum bactericidal
concentrations of G2-PEG- and SO-modified dendrimers (3 and 5) still inhibited fibroblast
proliferation by approximately 76 and 64%, respectively (i.e., 24 and 36% viability). Prior
studies have documented generation-dependent toxicity of cationic dendrimers to fibroblasts
and other mammalian cell types, clearly indicating that larger dendrimers generally exhibit
greater cytotoxicity, consistent with our observations.61,62,65
The toxicity of NO-releasing dendrimers 1a–6a to L929 fibroblasts was minimal (≥60%
viability; Figure 8) relative to controls 1–6 (Figure 7) when administered at both the
minimum and twice the minimum concentration required to elicit 3-log killing against all
tested bacterial strains. Such reduced toxicity is not surprising due to the lower
concentrations required for bacteria killing, and may also be attributed to decreased initial
cationic charges as evidenced by the less positive zeta potentials for the NO-releasing
dendrimers (Table 2). Due to proton-driven dissociation of N-diazeniumdiolates to NO, the
toxicity of the resulting dendrimer precursors 1–6 (i.e., control dendrimers) to fibroblasts
was also evaluated at equivalent doses of their NO-releasing analogues 1a–6a that proved
Sun et al. Page 10













bactericidal (Figure 8). These results reveal minimal toxicity for the dendrimer precursors at
these concentrations, even though a ~75% reduction in fibroblast viability was observed for
the G5-PPI-PEG precursor 4 at the bactericidal concentration of its N-diazeniumdiolate-
modified derivative 4a (20 μM; Figure 8B). Remarkably, both G2 and G5 NO-releasing
PPI-SO dendrimers (5a and 6a) and their precursors (5 and 6) proved to be nontoxic to the
fibroblast cells (>80 % viability; Figure 8) even at concentrations necessary to induce 5-log
killing against all species studied (10 and 1 μM, respectively; Table 5). Collectively, these
results illustrate the potential of NO-releasing dendrimers as effective scaffolds for
combating bacteria with minimal toxicity to healthy mammalian cells.
Conclusions
The utility of NO-releasing dendrimers as antibacterial therapeutics with broad-spectrum
activity was demonstrated through the systematic study of dendrimer size, NO release, and
exterior modification. In general, NO-releasing PPI dendrimers exert increased bactericidal
activity at concentrations lower than the corresponding antibacterial precursors. The
antibacterial efficacy observed across a series of structurally diverse NO-releasing dendritic
scaffolds was largely dependent on size and exterior functionality (e.g., hydrophobicity,
biocompatibility, etc.). The benefit of NO-releasing dendrimers over quaternary ammonium-
functionalized scaffolds was illustrated by their limited toxicity against fibroblasts at
concentrations necessary to eradicate bacteria (3-log killing). In particular, G2 and G5 NO-
releasing PPI-SO dendrimers proved highly effective (≥99.999% killing) against both Gram-
positive and Gram-negative bacteria, including the antibiotic-resistant strain, MRSA, while
maintaining minimal toxicity against mammalian cells at bactericidal doses. Experiments are
underway to examine the possible role of NO-release kinetics on antibacterial efficacy (i.e.,
short versus extended NO release). Future studies are also planned to exploit the versatility
of the exterior modification using multi-NO donor functionalization and specific ligand
conjugation strategies (e.g., sugars, antibodies, etc.) that may further enhance the utility of
NO-releasing dendritic scaffolds as antibacterial agents.
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Structures of secondary amine- and N-diazeniumdiolate NO donor-functionalized G2 (n = 8)
and G5 (n = 64) PPI dendrimers.
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Viability of Gram-negative P. aeruginosa after 2 h exposure to a range of optimized
concentrations of control and NO-releasing PPI dendrimers with (A) G2-PO; (B) G5-PO;
(C) G2- PEG; (D) G5-PEG; (E) G2-SO; and, (F) G5-SO modifications.
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Bright field and fluorescent images of P. aeruginosa cells exposed to the same NO dosage
(10 μmol·L−1) via incubation with NO-releasing G2- and G5-PPI-SO (8.7 and 10 μg·mL−1,
respectively) and 50 nm AHAP3/TEOS nanoparticles (22 μg·mL−1). Intracellular NO is
indicated by the appearance of DAF-2 green fluorescence, while PI red fluorescence
indicates compromised membranes (cell death). Images were acquired (A) 30; (B) 46; (C)
60; (D) 64; (E) 86; and, (F) 94 min after dendrimer/nanoparticle addition.
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Viability of Gram-positive S. aureus after 2 h exposure to a range of optimized
concentrations of control and NO-releasing PPI dendrimers with (A) G2-PO; (B) G5-PO;
(C) G2- PEG; (D) G5-PEG; (E) G2-SO; and, (F) G5-SO modifications.
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Bright field and fluorescent images of RITC-modified control and NO-releasing G2 PPI-PO
dendrimer (400 μg·mL−1) association with S. aureus cells. Images were acquired (A) 4; (B)
12; (C) 18; (D) 30; and, (E) 45 min following dendrimer addition.
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Comparison of the bactericidal efficacies of control and NO-releasing (A) G2 and (B) G5
PPI-SO dendrimers against methicillin-resistant S. aureus (MRSA) after 2h exposure.
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Toxicity of G2 (odd number) and G5 (even number) control PPI dendrimers to L929 mouse
fibroblasts at both the minimum concentration (light gray) and twice the minimum
concentration (black) necessary for 3-log killing against all bacterial strains tested.
Dendrimer concentrations are shown above in μM.
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Cytotoxicity of (A) G2 and (B) G5 NO-releasing PPI dendrimers 1a–6a including the
corresponding control scaffolds 1–6 (dendrimer precursors) against L929 mouse fibroblasts
at the minimum concentration (light gray) and twice the minimum concentration (black) of
NO-releasing dendrimers 1a–6a necessary for 3-log killing against all the bacterial strains
tested. Dendrimer concentrations are shown in μM.
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Table 2
Zeta potential of control and NO-releasing dendrimers in phosphate buffer (10 mM, pH = 7.4)
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Table 3
Comparison of the bactericidal efficacy (3-log killing) of control and NO-releasing PPI dendrimers against
Gram-negative P. aeruginosa after 2 h exposure
Dendrimer MBC (μM) MBC (μg·mL−1) Bactericidal NO Dose (μmol·L−1)
1 PPI-8-PO 400 484.0 —
1a PPI-8-PONO 300 242.0 897
2 PPI-64-PO 40 434.3 —
2a PPI-64-PONO 10 108.6 284
3 PPI-8-PEG 4800 22009 —
3a PPI-8-PEG-NO 320 1467.3 1254
4 PPI-64-PEG 80 3029 —
4a PPI-64-PEG-NO 20 757.2 492
5 PPI-8-SO 5 8.5 —
5a PPI-8-SO-NO 1 1.7 2.0
6 PPI-64-SO 5 74.1 —
6a PPI-64-SO-NO 0.5 7.4 7.6
7 PPI-8-NH2 320 238.5 —
8 PPI-64-NH2 20 142.8 —
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Table 4
Comparison of the bactericidal efficacy (3-log killing) of control and NO-releasing PPI dendrimers against
Gram-positive S. aureus after 2 h exposure
Dendrimer MBC (μM) MBC (μg·mL−1) Bactericidal NO Dose (μmol·L−1)
1 PPI-8-PO 400 484.0 —
1a PPI-8-PO-NO 800 967.9 2392
2 PPI-64-PO 2.5 27.1 —
2a PPI-64-PO-NO 0.5 5.4 14.2
3 PPI-8-PEG 3200 14673 —
3a PPI-8-PEG-NO 1200 5502 4703
4 PPI-64-PEG 20 757.2
4a PPI-64-PEG-NO 10 378.6 246
5 PPI-8-SO 10 17.1 —
5a PPI-8-SO-NO 5 8.5 10.1
6 PPI-64-SO 0.5 7.4 —
6a PPI-64-SO-NO 0.5 7.4 7.6
7 PPI-8-NH2 320 238.5 —
8 PPI-64-NH2 2.5 17.8 —
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